Strategic CSO Hire ATUM appointed Gavin Barnard as Chief Scientific Officer in April 2026, signaling a focus on scientific leadership and potential for expanded R&D partnerships and higher-level collaboration opportunities with pharma and biotech firms.

Leap-In Platform Leverage ATUM's Leap-In Transposase technology and ML-driven design to offer clients faster sequence to Research Cell Bank workflows, enabling efficiency gains, regulatory readiness, and scalable gene design, synthesis, and cell line development services.

Expanded Partnerships Recent collaboration with AGC Biologics to integrate Leap-In into their Cell Line Development Center of Excellence highlights ATUM’s licensing and co-development potential with large CDMOs, suggesting avenues for joint programs and technology incorporation.

Discovery and Production Launch of discoCHO Discovery Cell Line for rapid transient production indicates opportunities to sell pilot-ready cell lines and rapid production capabilities to biotech developers seeking fast hypothesis testing and manufacturing-ready solutions.

Financial Scale With a reported revenue range of 250–500 million and a mid-sized employee base, ATUM presents a balance of scale and agility ideal for strategic enterprise deals, multi-year collaborations, and integration into larger bio-manufacturing ecosystems.